Raynaud Fenomeni
Özet
Raynaud fenomeni, el ve ayak parmaklarındaki küçük arterlerin geçici ve tekrarlayan vazospazmı nedeniyle oluşan, ağrılı bir vasküler durumdur. Dijital arterlerin anormal vazokonstriksiyonu sonucu ortaya çıkan bu tablo, klinikte sırasıyla beyaz (iskemi), mavi (siyanoz) ve kırmızı (reperfüzyon) cilt rengi değişimleriyle karakterize üç evreden oluşur. Toplumun %3-5’inde görülen bu hastalık, kadınlarda erkeklere oranla dört kat daha yaygındır ve genellikle 30 yaş civarında başlar. Vakaların %80-90’ını oluşturan primer tip, altta yatan bir neden olmaksızın genellikle iyi huylu seyrederken; sekonder tip, bağ dokusu hastalıkları (özellikle sistemik skleroz), ilaçlar veya travma gibi ikincil nedenlere bağlı olarak gelişerek kangren ve dijital ülser gibi ciddi komplikasyonlara yol açabilir. Tanı klinik bulgularla konur; ancak primer ve sekonder ayırımı tedavi planı için kritiktir. Bu ayrımda antinükleer antikor (ANA) testi ve tırnak yatağına uygulanan kapilleroskopi yöntemi belirleyicidir. Tedavinin ilk basamağı koruyucu önlemler, soğuktan kaçınma ve sigarayı bırakma gibi yaşam tarzı değişiklikleridir. Medikal tedavide birinci basamakta kalsiyum kanal blokörleri tercih edilirken, dirençli ve komplike vakalarda fosfodiesteraz tip 5 inhibitörleri, intravenöz ilioprost veya dijital sempatektomi gibi ileri tedavi seçenekleri uygulanmaktadır.
Raynaud's phenomenon is a painful vascular condition characterized by recurrent, transient vasospasm of the small arteries in the fingers and toes. Caused by abnormal vasoconstriction of digital arteries, the classic clinical presentation involves a triphasic skin color change: white (ischemia), blue (cyanosis), and red (reperfusion). Affecting 3-5% of the general population, it is four times more prevalent in women than men and typically manifests around the age of 30. While primary Raynaud's accounts for 80-90% of cases, follows a benign course, and lacks an underlying cause, secondary Raynaud's develops due to connective tissue diseases (most notably systemic sclerosis), drugs, or trauma, and can lead to severe complications like digital ulcers and gangrene. Diagnosis is clinical; however, differentiating between primary and secondary types remains critical for management. Antinuclear antibody (ANA) testing and nailfold capillaroscopy are vital non-invasive tools used for this differentiation. Initial management emphasizes conservative measures, including smoking cessation and avoiding cold exposure. Pharmacologically, calcium channel blockers are the first-line therapy, whereas phosphodiesterase type 5 inhibitors, intravenous iloprost, or digital sympathectomy are reserved for severe or complicated cases.
Referanslar
Maciejewska M, Sikora M, Maciejewski C et all.Raynaud's Phenomenon with Focus on Systemic Sclerosis. J Clin Med. 2022 Apr 28;11(9):2490. doi: 10.3390/jcm11092490. PMID: 35566614; PMCID: PMC9105786.
Sezer M. , Çelikel E. , Aydın F. Et all. Evaluation of Primary and Secondary Raynaud’s Phenomenon in Childhood. Türkiye Çocuk Hastalıkları Dergisi. 2022; 1-6.
Anderson PO. Drug Treatment of Raynaud's Phenomenon of the Nipple. Breastfeed Med. 2020 Nov;15(11):686-688. doi: 10.1089/bfm.2020.0198. Epub 2020 Jul 17. PMID: 32700966.
Devgire V, Hughes M. Raynaud's phenomenon. Br J Hosp Med (Lond). 2019 Nov 2;80(11):658-664. doi: 10.12968/hmed.2019.80.11.658. PMID: 31707892.)
Pauling, J.D., Hughes, M. & Pope, J.E. Raynaud’s phenomenon—an update on diagnosis, classification and management. Clin Rheumatol 38, 3317–3330 (2019). https://doi.org/10.1007/s10067-019-04745-5
Yekin U, Gurbuz A, . Current Approach To Raynaud’s Phenomenon. Turk Gogus ve Kalp Damar cerrahi dergisi 2002;10:56-62
Temprano KK. A Review of Raynaud's Disease. Mo Med. 2016 Mar-Apr;113(2):123-6. PMID: 27311222; PMCID: PMC6139949.)
Baron M, Bell M, Bookman A, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007;26:1268–74.
Hughes M, Moore T, O’Leary N, et al. A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders. Rheumatology (Oxford) 2015;54:1435–42]
F.M. Meier, K.W. Frommer, R. Dinser, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database .Ann Rheum Dis, 71 (2012), pp. 1355-1360
C.E. Pain, T. Constantin, N. Toplak, et al. Paediatric Rheumatology European Society (PRES) Juvenile Scleroderma Working Group. Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clin Exp Rheumatol, 34 (Suppl 100) (2016), pp. S200-S206
Sharp C, Akram Q, Hughes M, Muir L, Herrick AL. Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature. Semin Arthritis Rheum 2016;46:209–16.
Haque A, Cleveland T, Powell L, et al. Large vessel disease as a potentially treatable cause of devastating critical digital ischaemia in systemic sclerosis. Clin Rheumatol 2020;39:2823–4.
Maricq HR, Carwile LeRoy E. Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 1973;16:619–28.
P. Moinzadeh, G. Riemekasten, E. Siegert, et al. Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. Rheumatol, 43 (2016), pp. 66-74
Herrick AL, Wigley FM. Raynaud's phenomenon. Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101474. doi: 10.1016/j.berh.2019.101474. Epub 2020 Jan 29. PMID: 32007400
O. Kowal-Bielecka, J. Fransen, J. Avouac, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis, 76 (2017), pp. 1327-1339
A. Fernandez-Codina, E. Canas-Ruano, J.E. Pope. Management of Raynaud's phenomenon in systemic sclerosis - a practical approach. J Scleroderma Relat Disord, 4 (2019), pp. 102-110
A.L. Herrick. Evidence based management of Raynaud's phenomenon, Ther Advances Musculoskeletal Dis, 9 (2017), pp. 317-329
O. Kowal-Bielecka, J. Fransen, J. Avouac, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis, 76 (2017), pp. 1327-1339
F.M. Wigley, R.A. Wise, J.R. Seibold, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study, Ann Intern Med, 120 (1994), pp. 199-206
J. Pope, D. Fenlon, A. Thompson, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis, Cochrane Database Syst Rev, 2 (2000), p. CD000953
A. Herrick, L. Muir. Raynaud's phenomenon (secondary). Clinical Evidence (Online). Clin Evid, 2014 (2014), p. 1125
